BioPharma Resources

NDA 218436 · Novartis

Rhapsido

Remibrutinib · Oral

NovelPriority review

CDER novel approval, Sep 30, 2025: To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Sep 30, 2025

Approved uses

2

Original approval plus efficacy supplements

Registered trials

34

22 Phase 3, 12 recruiting

FAERS reports

1,354

267 serious, 1 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. FDA's summary: To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 6, 2026 Supplement 1 · Efficacy LetterLabel
  • Sep 30, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
  • RHAPSIDO · REMIBRUTINIB 25MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Remibrutinib" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urticaria186
  • petechiae185
  • drug ineffective148
  • contusion130
  • pruritus105
  • headache77
  • heavy menstrual bleeding59
  • nausea58
  • off label use57
  • condition aggravated53
  • chronic spontaneous urticaria44
  • rash40

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20249
2025234
20261,111

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.